Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Efficacy of MEN2312 (KAT6 Inhibitor) in Participants With Hematological Malignancies

NCT07873827 is registered in ClinicalTrials.gov with Stemline Therapeutics, Inc. as lead sponsor.

NCT NCT07873827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07873827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Efficacy of MEN2312 (KAT6 Inhibitor) in Participants With Hematological Malignancies
Lead sponsor
Stemline Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
May 12, 2030
Enrollment
115 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hematological malignancy